A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Clinical trial NCT03239340 · COMPLETED

Trial details

NCT number: NCT03239340
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Start date: 2018-05-30
Primary completion: 2023-09-19
Enrollment: 154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.